Allergy Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Eye Allergy, Rhinitis, Asthma, Skin Allergy, Food Allergies, Other Allergies), By Treatment (Anti-Allergy Drugs, Immunotherapy), By Distribution Channel (Hospital, Online Pharmacies, Retail Pharmacies, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 23.87 Billion
CAGR (2026-2031)	8.01%
Fastest Growing Segment	Anti-Allergy Drugs
Largest Market	North America
Market Size (2031)	USD 37.91 Billion

Market Overview

The Global Allergy Care Market will grow from USD 23.87 Billion in 2025 to USD 37.91 Billion by 2031 at a 8.01% CAGR. The Global Allergy Care Market comprises a diverse range of diagnostics, pharmaceuticals, and immunotherapies designed to identify, alleviate, and treat immune system hypersensitivities triggered by environmental, dietary, or pharmaceutical allergens. The primary drivers fueling market growth include the rising prevalence of allergic conditions resulting from increasing urbanization, elevated pollution levels, and shifting dietary habits globally. Furthermore, heightened public awareness regarding early diagnosis and management is accelerating the demand for over-the-counter and prescription solutions. According to the Asthma and Allergy Foundation of America, in 2025, more than 100 million individuals in the United States experience various types of allergies each year.

Despite this robust demand, the market faces a significant impediment related to the affordability of advanced care. The high costs associated with sophisticated diagnostic procedures and long-term immunotherapy treatments restrict accessibility for a substantial portion of the population, particularly in developing nations. This economic barrier limits widespread adoption and remains a critical challenge that could hinder the anticipated expansion of the global allergy care sector.

Key Market Drivers

Advancements in immunotherapy and novel biologics are fundamentally reshaping the global allergy care market by shifting the focus from temporary symptom relief to long-term desensitization and disease modification. The recent introduction of targeted biological therapies has provided groundbreaking options for patients with severe IgE-mediated food allergies who previously relied solely on avoidance strategies. According to Genentech, February 2024, in the 'FDA Approves Xolair' press release, 67% of participants in the Phase III OUtMATCH study treated with the biologic could ingest a single dose of 600 mg of peanut protein without moderate to severe symptoms. This ability to significantly raise the reaction threshold is driving the widespread adoption of high-value prescription treatments, thereby expanding the commercial potential of the sector as healthcare providers integrate these sophisticated regimens into standard care protocols.

The impact of rapid urbanization and environmental pollution serves as a second critical driver, as climate change intensifies allergen exposure and dramatically extends respiratory allergy seasons. Rising global temperatures are causing plants to bloom earlier and produce higher pollen concentrations, compelling a larger demographic to seek continuous medical intervention. According to CBS News, April 2024, in the article 'Seasonal allergies are here for spring 2024', data from the USA National Phenology Network indicated that spring conditions arrived up to 23 days early in major urban centers like Detroit compared to long-term averages. This environmental shift is fueling substantial revenue growth for major pharmaceutical players as patient demand for effective management solutions escalates. According to Sanofi, in 2024, sales of the blockbuster immunology medication Dupixent surged by 29.2% in the second quarter to reach €3,303 million.

Download Free Sample Report

Key Market Challenges

The high cost of specialized diagnostics and long-term immunotherapy treatments constitutes a primary obstacle to the expansion of the Global Allergy Care Market. Although the prevalence of hypersensitivities is rising, the substantial expense associated with comprehensive care restricts accessibility for a large segment of the global population. This economic barrier is particularly pronounced in developing nations and among uninsured demographics, where patients often forgo necessary disease management in favor of temporary, lower-cost symptomatic relief. Consequently, the market struggles to convert the high volume of potential patients into consistent revenue streams, thereby limiting the scalability of therapeutic solutions in price-sensitive regions.

The impact of these financial constraints is statistically evident and underscores the severity of the affordability gap. According to the European Academy of Allergy and Clinical Immunology, in 2025, the average total cost per patient per year for allergic diseases was reported to be €1,329.55. This significant financial requirement impedes the widespread adoption of sustained treatment plans, directly hampering the industry's ability to maximize its growth potential and penetration across diverse global markets.

Key Market Trends

The Global Allergy Care Market is witnessing a decisive shift towards Sublingual Immunotherapy (SLIT) as a preferred therapeutic alternative to traditional subcutaneous injections. This trend is characterized by the accelerating adoption of standardized allergen tablets, which allow patients to self-administer disease-modifying treatments at home, thereby eliminating the logistical burden of frequent clinic visits required for shot-based protocols. This transition toward non-invasive care is significantly expanding the addressable patient pool for respiratory allergies, driving revenue growth through improved adherence and convenience. The commercial success of this modality is underscored by the performance of major industry players. According to ALK-Abelló, February 2025, in the 'Annual report 2024', tablet sales increased by 24% to reach DKK 2,851 million, driven largely by volume growth and improved pricing strategies in European markets.

Concurrently, the Rise of Digital Health and Tele-Allergy Platforms is fundamentally altering service delivery by bridging the accessibility gap between patients and specialists. Healthcare providers are increasingly deploying integrated digital ecosystems that utilize electronic consultations and remote triage systems to manage patient flow, ensuring that in-person medical resources are reserved for complex, high-risk cases. This digital transformation optimizes clinical efficiency and allows for the effective management of allergic conditions without the need for physical presence, directly addressing infrastructure constraints. The operational impact of this shift is statistically evident in recent clinical data. According to Frontiers in Allergy, April 2024, in the article 'The paradigm shift in allergy consultations through a digital ecosystem', data from the implementation of a digital referral system revealed that 42.8% of electronic consultations from primary care in 2023 were successfully resolved without requiring a face-to-face appointment.

Segmental Insights

According to trusted market intelligence, the Anti-Allergy Drugs segment is currently the fastest growing category within the Global Allergy Care Market. This rapid expansion is primarily driven by the escalating prevalence of chronic respiratory and skin allergies, exacerbated by rising urbanization and environmental pollution. Furthermore, the segment benefits significantly from supportive regulatory actions, such as the U.S. Food and Drug Administration (FDA) approving the switch of various prescription formulations to over-the-counter status. This shift improves accessibility and affordability, thereby increasing consumer adoption of self-medication for immediate symptom relief.

Regional Insights

North America holds the leading position in the global allergy care market, driven primarily by the high prevalence of respiratory and food allergies across the region. This dominance is supported by well-established healthcare infrastructure and substantial healthcare expenditure that ensures widespread access to diagnostic and therapeutic solutions. The presence of key industry players fosters consistent product availability, while the U.S. Food and Drug Administration provides a structured regulatory environment for the approval of new treatments. Additionally, favorable reimbursement policies encourage patient adoption of allergy therapies, further strengthening the regional market.

Recent Developments

• In October 2025, Stallergenes Greer announced positive results from its Phase IIIb clinical study, known as YOBI, which evaluated the safety and efficacy of its sublingual immunotherapy treatment, Staloral Birch. The study, involving children and adolescents suffering from birch pollen-induced allergic rhino-conjunctivitis, successfully met its primary endpoint, demonstrating a statistically significant reduction in symptoms and medication use compared to a placebo. These findings reinforce the clinical value of the company's allergen immunotherapy solutions and support its efforts to provide effective, long-term treatments for pediatric patients with respiratory allergies.
• In November 2024, ALK-Abelló announced a strategic licensing agreement with ARS Pharmaceuticals to acquire exclusive rights to commercialize neffy, an adrenaline nasal spray, in Europe, Canada, and other global markets excluding the United States, Australia, New Zealand, Japan, and China. Under the terms of the collaboration, ALK-Abelló agreed to an upfront payment and potential future milestone payments to expand its portfolio with this needle-free anaphylaxis treatment. This partnership aims to leverage ALK-Abelló's established presence in the allergy immunotherapy space to accelerate the availability of this innovative emergency treatment in key international regions.
• In August 2024, ARS Pharmaceuticals achieved a significant milestone with the FDA approval of neffy (epinephrine nasal spray) for the treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing at least 30 kilograms. This approval marked the introduction of the first needle-free emergency epinephrine treatment, offering a less invasive alternative to traditional auto-injectors. The product is designed to provide rapid absorption and reliable efficacy comparable to injectable epinephrine, addressing a critical need for patients who may be hesitant to use needle-based devices during severe allergic episodes.
• In February 2024, Genentech, a member of the Roche Group, received approval from the U.S. Food and Drug Administration (FDA) for Xolair (omalizumab) as the first medication to reduce allergic reactions to multiple foods following accidental exposure. The approval covers adults and children aged one year and older with Immunoglobulin E (IgE)-mediated food allergies. While the treatment does not eliminate food allergies or allow patients to consume allergens freely, it is designed to minimize the risk of severe reactions, including anaphylaxis, if they accidentally ingest foods such as peanuts, milk, eggs, or cashews.

Key Market Players

• ALK-Abelló A/S
• AbbVie Inc.
• Allergy Therapeutics PLC
• Bausch Health Companies Inc.
• Alembic Pharmaceuticals Limited
• F. Hoffmann-La Roche Ltd
• Nicox SA
• GlaxoSmithKline PLC
• Johnson & Johnson
• LETI Pharma, S.L.U

By Type	By Treatment	By Distribution Channel	By Region
Eye Allergy Rhinitis Asthma Skin Allergy Food Allergies Other Allergies	Anti-Allergy Drugs Immunotherapy	Hospital Online Pharmacies Retail Pharmacies Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Allergy Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Allergy Care Market, By Type:

• Eye Allergy
• Rhinitis
• Asthma
• Skin Allergy
• Food Allergies
• Other Allergies

• Allergy Care Market, By Treatment:

• Anti-Allergy Drugs
• Immunotherapy

• Allergy Care Market, By Distribution Channel:

• Hospital
• Online Pharmacies
• Retail Pharmacies
• Others

• Allergy Care Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE